Physician profile
Kenneth E Mcclure
NPI 1770550311
$2,147.32
in general payments reported to CMS, 2019-2025
30 companies · $423 in 2025
The $423 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $264 · 2020: $475 · 2021: $387 · 2022: $61.13 · 2023: $162 · 2024: $376 · 2025: $423.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $941 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $941.07 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $657.94 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $260.93 | 2020-2025 | |
| Glaxosmithkline, LLC. | $200.43 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $134.10 | 2019-2020 | |
| Amgen INC. | $97.56 | 2020-2024 | Krystexxa, Otezla, Repatha |
| Lilly USA, LLC | $85.29 | 2020-2024 | Jardiance |
| Pfizer INC. | $64.47 | 2020-2025 | |
| Axsome Therapeutics, INC. | $63.01 | 2025 | Auvelity, Symbravo |
| Janssen Pharmaceuticals, INC | $55.77 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.25 | 2020-2021 | |
| Avanir Pharmaceuticals, INC. | $42.85 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $42.39 | 2023-2025 | |
| Amarin Pharma, INC. | $42.17 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $32.91 | 2019 | |
| Currax Pharmaceuticals LLC | $31.64 | 2021-2024 | Contrave |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $27.52 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $25.16 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.70 | 2021 | |
| Inspire Medical Systems, INC. | $23.55 | 2025 | Inspire |
| Acadia Pharmaceuticals INC | $23.02 | 2024 | Daybue |
| Cequr Corporation | $19.65 | 2025 | Cequr Simplicity |
| Almatica Pharma LLC | $18.77 | 2024 | Loreev Xr |
| Phathom Pharmaceuticals, INC. | $18.56 | 2024 | Voquezna |
| Otsuka America Pharmaceutical, INC. | $17.92 | 2025 | Rexulti |
| Astellas Pharma US INC | $17.20 | 2020 | |
| Abiomed | $16.51 | 2025 | |
| Eisai INC. | $16.06 | 2020 | |
| Ge Healthcare | $15.29 | 2019 | |
| Sanofi-Aventis U.S. LLC | $11.95 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.75 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Mcclure listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.